Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | The current treatment landscape for AML

Christoph Röllig • 8 Dec 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Venetoclax

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the latest advancements in the treatment of acute myeloid leukemia (AML). Successful novel agents with varying mechanisms of action are increasingly making their way into clinical practice. Venetoclax is an exciting agent currently used in several different combinations in AML. Tyrosine kinase inhibitors and immunotherapies are also areas of interest in AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Christoph Röllig

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML
2:41
Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML
Christoph Röllig • 5 Dec 2025
Challenges associated with relapsed AML and the value of targeted agents
2:52
Challenges associated with relapsed AML and the value of targeted agents
Christoph Röllig • 3 Sep 2025
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML
2:18
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML
Christoph Röllig • 3 Sep 2025
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals